

Łomianki, 11.04.2017r.

Purchaser:

Celon Pharma S.A.

Mokra 41A

05-092 Łomianki / Kielpin

tel.: +48 22 751 74 78

fax: +48 22 751 74 77

KRS: 0000437778

NIP: 118 - 16 - 42 - 061

e-mail: dominika.kasprowiak@celonpharma.com

Bidders involved in the procedure

Notification for the extension of the evaluation period of Request for Quotation (RfQ) no. 11/2017/M/CELONKO regarding research work to be subcontracted in the area of general toxicology, safety pharmacology and analytical support studies program via the intended route of administration in the project: “Development of novel biomarkers and innovative FGFR kinases inhibitor as an anti-cancer therapy” as part of the 2nd edition of the contest in the research and development program: “Prevention and treatment of civilization diseases – STRATEGMED”.

Statement of reasons

This has been necessitated by the complexity of the tendering procedure and the need for explanations and analysis of the bids. The final decision will be communicated on **21.04.2017**. The decision is pursuant to Article 28 of the Request for Quotation (RfQ) no. 11/2017/M/CELONKO (20th March, 2017).

Celon Pharma S.A.

HQ Office: Ogródowa 2A, Kielpin

05-092 Łomianki, Poland

phone: +48 22 751 59 33

fax: +48 22 751 44 58

e-mail: info@celonpharma.com

Registering authority: District Court for the Capital City of Warsaw,

14th Commercial Department of the National Court Register

President of the Management Board: Maciej Wieczorek

National Court Register entry number (KRS): 0000437778

Share capital: 3 000 000 PLN

Tax ID number (NIP) : 118 – 16 – 42 – 061

www.celonpharma.com